On December 16, 2021, Pear Therapeutics announced that it has acquired two prescription digital therapeutic (PDT) assets that are designed for the treatment of a “spectrum of depression conditions.” One PDT was acquired from Waypoint Health Innovations, LLC. The second is from a researcher named Fredrik Holländare of Örebro University. Pear intends to incorporate both assets into Pear’s depression platform. However, no timeline for this development has been announced.
The asset acquired from Waypoint Health Innovations is a digital therapeutic designed for treatment of depression based on structured and proven cognitive behavioral therapy (CBT) techniques. The Waypoint asset . . .